Cardiovascular Research in EMbarazo and MAternity (EMMA). Study on Heart Rate Variability and Hemodynamic Adaptations During Pregnancy and Postpartum.

Fundacin Biomedica Galicia Sur

Status: Active, not recruiting

Conditions: Heart Rate Variation (HRV); Pregnancy Related; Hemodynamics

Treatments: Other: Assessment of HRV and blood pressure

Study type: Observational

Funder types: Other

Identifiers

NCT07376616

EMMA

Details and patient eligibility

About

Heart rate variability (HRV) provides a non-invasive assessment of autonomic control of the nervous system over the heart. During pregnancy, the cardiovascular system adapts significantly, affecting HRV and hemodynamics. Studying the relationship between HRV and hemodynamic changes is critical to understanding and monitoring cardiovascular health during pregnancy and postpartum, and predicting potential complications.

Enrollment: 242 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Over 18 years of age
• Pregnancy from the third month of gestation
• No pre-existing cardiovascular disease
• Good cognitive level
• Sign informed consent

Exclusion criteria

• Diabetes mellitus
• Hyperthyroidism
• Hypothyroidism
• Chronic hypertension diagnosed before pregnancy
• Heart failure
• Ischemic heart disease or malignant ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia, grade 2 or 3 AV block, atrial fibrillation in patients with Wolff-Parkinson- White syndrome, paroxysmal fibrillation or flutter with rapid ventricular response and hemodynamic deterioration, uncontrolled supraventricular tachycardia)
• Exercise-induced ischaemia
• Unstable angina
• Disease not susceptible to revascularization
• Associated valvular heart disease
• Chronic kidney disease
• Degenerative neurological condition
• Brain aneurysms
• Arteriovenous malformations
• History of transient cerebral infarction (ICTUS)
• Migraines diagnosed
• Epilepsy
• Brain or spinal cord injury
• Tumors
• Diseases of the respiratory tract
• Diseases of lung tissue
• Diseases of pulmonary circulation

Trial design

242 participants in 1 patient group

Unic group

Treatment:

Other: Assessment of HRV and blood pressure